Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes.
IFN-gamma, a pleiotropic immune regulator, is implicated in both tumor immune surveillance and selection of tumor variants resistant to immune control, i.e., immunoediting. In uveal melanoma patients, elevated serum levels of IFN-gamma correlate with the spread of metastasis and represent a negative prognostic marker. Treatment with IFN-gamma boosted the MHC class I presentation machinery in uveal melanoma cells but suppressed their MHC class I-restricted CTL lysis. Tumor cells exposed to IFN-gamma efficiently activated specific CTL but were less susceptible to permeabilization by perforin and exhibited a decreased capacity to bind and incorporate granzyme B. These results define a novel mechanism of resistance to granule-mediated CTL lysis in human tumors. Furthermore, the data suggest that immunoediting is not limited to genetic or epigenetic changes resulting in stable cellular phenotypes but also involves an inducible modulation of tumor cells in response to a microenvironment associated with immune activation.
Hallermalm
Kristian
K
Cancer Centrum Karolinska, Karolinska Institutet, Stockholm, Sweden.
Seki
Kazutake
K
De Geer
Anna
A
Motyka
Bruce
B
Bleackley
R Chris
RC
Jager
Martine J
MJ
Froelich
Christopher J
CJ
Kiessling
Rolf
R
Levitsky
Victor
V
Levitskaya
Jelena
J
D014408:Biomarkers, Tumor / Q000097:blood / Q000502:physiology; D045744:Cell Line, Tumor; D002463:Cell Membrane Permeability / Q000276:immunology; D002999:Clone Cells; D003602:Cytotoxicity, Immunologic; D015536:Down-Regulation / Q000276:immunology; D053804:Granzymes / Q000037:antagonists & inhibitors / Q000502:physiology*; D006801:Humans; D007108:Immune Tolerance; D007113:Immunity, Innate / Q000276:immunology; D016130:Immunophenotyping; D007371:Interferon-gamma / Q000097:blood / Q000502:physiology*; D008545:Melanoma / Q000276:immunology* / Q000378:metabolism / Q000473:pathology / Q000556:secondary; D054353:Perforin / Q000502:physiology; D011379:Prognosis; D015398:Signal Transduction / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000201:enzymology / Q000276:immunology* / Q000378:metabolism; D015854:Up-Regulation / Q000276:immunology; D014604:Uveal Neoplasms / Q000201:enzymology / Q000276:immunology* / Q000473:pathology
D014408:Biomarkers, Tumor; D054353:Perforin; D007371:Interferon-gamma; D053804:Granzymes